On Thursday, Abbott Laboratories stock earned a positive adjustment to its Relative Strength (RS) Rating, from 78 to 82. The medical device firm recently announced a collaboration with Tandem Diabetes Care to develop automated insulin delivery systems using a dual glucose-ketone sensor.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary rating measures share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating of at least 80 as they begin their biggest climbs.
Is Abbott Laboratories Stock A Buy?
Abbott Laboratories stock is working on a cup with tight handle with a 136.80 entry. See if the medical stock can break out in heavy volume.
The diversified medical device company reported 11% EPS growth in its most recent report. Revenue increased 4%.
Abbott Laboratories stock earns the No. 2 rank among its peers in the Medical-Diversified industry group. Eli Lilly is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
